Disruptive Technology Award

The AACC Disruptive Technology Award recognizes innovative testing solutions that improve patient care through diagnostic performance or access to high quality testing. The competition provides a unique opportunity to showcase your technology, receive feedback and mentorship from an expert panel of reviewers, and to connect with leaders in the in vitro diagnostics industry and research community. Finalists also have the opportunity to present their technology at the AACC Annual Scientific Meeting, which draws up to 20,000 laboratory medicine professionals from around the world.

FINALISTS

Congratulations to the 2020 AACC Disruptive Technology Award finalists:

ALCEDIAG
Precision diagnostics is still a major unmet medical need in psychiatry. Thanks to epigenetics enhanced by artificial intelligence, ALCEDIAG is changing the game. The company’s EditB blood test helps differentiate depression from bipolar disorder with an accuracy of 87%.

Baebies
Nearly 10% of all babies born are admitted to the neonatal intensive care unit, where they are evaluated using tests intended for adults that require large sample volumes. Baebies addresses unmet needs in neonatal diagnostics with panels of tests using low sample volume.

Sherlock Biosciences
Sherlock is disrupting diagnostics with better, faster, and more affordable tests designed to improve health worldwide in virtually any setting without complex instruments.

SEMIFINALISTS

Congratulations as well to the 2020 AACC Disruptive Technology Award semifinalists:

Cardea Bio
In a true first, Cardea’s Biology-gated Transistors infrastructure directly connects biology with computers. Together with our innovation partners, Cardea is developing an infrastructure of products and applications that Link up to Life.

Geneoscopy
Geneoscopy is a healthcare startup company that has developed a novel method to extract eukaryotic RNA biomarkers from stool to enable a new wave of noninvasive diagnostic tests to prevent, detect, and treat gastrointestinal disease.

Zepto Life Technology
Zepto aims to replace blood culture with a rapid point-of-care molecular diagnostic platform that identifies pathogen cell-free DNA directly from plasma. Zepto uses giant magnetoresistance or GMR, which combines microarray and melting curves to yield unparalleled diagnostic accuracy.

Special thanks as well to our expert reviewers for their valuable time and feedback during the execution and planning of this event.

Timeline

• June 15: Deadline for application submission. 
  
• August 12: Semifinalists announced. 
• Late August–Mid-September: Semifinalist presentation to award committee.
• September 30: Finalists announced.
• Mid-October: Finalists and assigned mentors coordinate further presentation review.
• December 14, 4:30–5:30 p.m. U.S. Central Time: Finalists required to present at this special session during the 2020 AACC Annual Scientific Meeting. The winner will be chosen at the end of the session. 

Please note that these dates may still be subject to change.

Questions?

Please contact education@aacc.org if you have any questions.